Related Experiment Video
Updated: Feb 13, 2026

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
Published on: January 6, 2014
Redefining Dendritic Cell Vaccines: Synergistically Co-priming DC and B Cells With Nanoparticles Loading Whole Cell
Xiangxiang Xu1,2,3,4,5, Xianlan Chen1,2, Jin Wang1,2
1Department of Pharmaceutics, College of Pharmaceutical Sciences, Soochow University, Suzhou, P. R. China.
Dendritic cells (DC) play core roles in inducing antigen-specific T cells. However, limited effectiveness hinders their applications as vaccines. To improve the efficacy of traditional DC vaccines, this study optimized three aspects: tumor antigens, cell sources and co-incubating molecules, and thus proposed a new DC-BC vaccine: co-priming B cells and DC at a precise ratio. The therapeutic efficacy was significantly improved by co-incubating DC and B cells. Regarding tumor antigens, utilizing nanoparticles loading whole-tumor lysates performed better than utilizing nanoparticles loading multiple neo-antigens, or nanoparticles loading only water-soluble lysates, or free whole-tumor lysates. Moreover, adding IL-15 and αPD-L1 antibody further bettered DC-BC vaccines. The optimal DC-BC vaccines showed excellent therapeutic efficacy with a 100% response rate and could cure most tumor-bearing mice on several different cancer models, including melanoma, lung cancer and orthotopic pancreatic cancer. The mechanism investigation demonstrated that several molecules, including Ticam1 (TRIF), Traf3, Mavs, and Ifnar2, were involved in promoting APC maturation and improving therapeutic efficacy of vaccines by activating innate immune pathways (TLR/NLR/RLR). In summary, this study provides a new DC-BC vaccine that has much better therapeutic efficacy and explores the underlying mechanism of why co-incubating DC and B cells improved the therapeutic efficacy.
Dendritic cells (DC) play core roles in inducing antigen-specific T cells. However, limited effectiveness hinders their applications as vaccines. To improve the efficacy of traditional DC vaccines, this study optimized three aspects: tumor antigens, cell sources and co-incubating molecules, and thus proposed a new DC-BC vaccine: co-priming B cells and DC at a precise ratio. The therapeutic efficacy was significantly improved by co-incubating DC and B cells. Regarding tumor antigens, utilizing nanoparticles loading whole-tumor lysates performed better than utilizing nanoparticles loading multiple neo-antigens, or nanoparticles loading only water-soluble lysates, or free whole-tumor lysates. Moreover, adding IL-15 and αPD-L1 antibody further bettered DC-BC vaccines. The optimal DC-BC vaccines showed excellent therapeutic efficacy with a 100% response rate and could cure most tumor-bearing mice on several different cancer models, including melanoma, lung cancer and orthotopic pancreatic cancer. The mechanism investigation demonstrated that several molecules, including Ticam1 (TRIF), Traf3, Mavs, and Ifnar2, were involved in promoting APC maturation and improving therapeutic efficacy of vaccines by activating innate immune pathways (TLR/NLR/RLR). In summary, this study provides a new DC-BC vaccine that has much better therapeutic efficacy and explores the underlying mechanism of why co-incubating DC and B cells improved the therapeutic efficacy.
More Related Videos
Related Concept Videos
Vaccinations
DC Generator
DC Battery
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Fast Decoupled and DC Powerflow
Antigen Presenting Cells
T cells require the help of antigen-presenting cells (APCs), which process foreign antigens into smaller fragments that can be recognized by T cells. These APCs are highly specialized cells that efficiently internalize antigens...

